Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease

Neurochemistry International

Volumn 79, Issue , 2014, Pages 1-11

  Yildirim, Fatos Belgin ^a   Ozsoy, Ozlem ^a   Tanriover, Gamze ^a   Kaya, Yasemin ^a   Ogut, Eren ^a   Gemici, Burcu ^a   Dilmac, Sayra ^a   Ozkan, Ayse ^a   Agar, Aysel ^a   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

6 Hydroxydopamine; Apoptosis; Cyclooxygenase; Melatonin; Nuclear factor kappa B; Prostaglandin E2

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; NITRATE; NITRITE; OXIDOPAMINE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; TYROSINE 3 MONOOXYGENASE; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL PARKINSONISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; RAT; SUBSTANTIA NIGRA; SUPPLEMENTATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; DOPAMINERGIC NEURONS; MALE; MELATONIN; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 84908514480     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2014.09.005     Document Type: Article

References (69)

1. Absi E. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain J. Pineal Res 29 1 2000 40 47
2. Adams J.D. Jr., Chang M.L., and Klaidman L. Parkinson's disease - redox mechanisms Curr. Med. Chem 8 7 2001 809 814
3. Andersen J.K. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Brain Res 656 1 1994 108 114
4. Aras S. The role of nitric oxide on visual-evoked potentials in MPTP-induced Parkinsonism in mice Neurochem. Int 72 2014 48 57
5. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly Am. J. Physiol 271 5 Pt 1 1996 C1424 C1437
6. Ben-Shachar D. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons J. Neurochem 56 4 1991 1441 1444
7. Bortolozzi A. Intracerebral administration of 2,4-diclorophenoxyacetic acid induces behavioral and neurochemical alterations in the rat brain Neurotoxicology 22 2 2001 221 232
8. Capitelli C. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats Eur. J. Pharmacol 594 1-3 2008 101 108
9. Cardinali D.P. Melatonin and mitochondrial dysfunction in the central nervous system Horm. Behav 63 2 2013 322 330
10. Chabrier P.E., Demerle-Pallardy C., and Auguet M. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases Cell. Mol. Life Sci 55 8-9 1999 1029 1035
11. Chen J. Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage J. Pineal Res 56 1 2014 12 19
12. Dabbeni-Sala F. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity FASEB J. 15 1 2001 164 170
13. Dastgheib M., and Moezi L. Acute and chronic effects of agomelatine on intravenous penthylenetetrazol-induced seizure in mice and the probable role of nitric oxide Eur. J. Pharmacol 736 2014 10 15
14. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models Neuron 39 6 2003 889 909
15. Dekundy A. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease Brain Res. Bull 69 3 2006 318 326
16. Dexter D.T. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J. Neurochem 52 2 1989 381 389
17. Esposito E. Non-steroidal anti-inflammatory drugs in Parkinson's disease Exp. Neurol 205 2 2007 295 312
18. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol. Pharmacol 14 4 1978 633 643
19. Graham D.G. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease Neurotoxicology 5 1 1984 83 95
20. Grealish S. Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat Brain Res. Bull 77 5 2008 312 319
21. Hacioglu G. Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease Folia Histochem. Cytobiol 50 2 2012 228 238
22. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease Adv. Neurol 45 1987 19 34
23. Horstink M.W., and Morrish P.K. Preclinical diagnosis of Parkinson's disease Adv. Neurol 80 1999 327 333
24. Jiang J., Zuo Y., and Gu Z. Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease Int. J. Mol. Med 31 4 2013 825 832
25. Jin B.K. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats Neurosci. Lett 245 2 1998 61 64
26. Jin F. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats Eur. J. Pharmacol 600 1-3 2008 78 82
27. Karadayian A.G. Effect of melatonin on motor performance and brain cortex mitochondrial function during ethanol hangover Neuroscience 269 2014 281 289
28. Kayir H. Clozapine inhibits develo60HDA-Melent and expression of nicotine-induced locomotor sensitization in rats Synapse 63 1 2009 15 21
29. Khaldy H. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion Neurobiol. Aging 24 2003 491 500
30. Kim H.A., Lee K.H., and Lee B.H. Neuroprotective effect of melatonin against kainic acid-induced oxidative injury in hippocampal slice culture of rats Int. J. Mol. Sci 15 4 2014 5940 5951
31. Kumar A. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms Brain Res 1471 2012 13 22
32. Lee H.J. Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease Neurochem. Res 35 4 2010 613 619
33. Levecque C. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study Hum. Mol. Genet 12 1 2003 79 86
34. Lin L. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease Life Sci 92 4-5 2013 311 316
35. Ma J., Shaw V.E., and Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat. Disord 15 4 2009 307 314
36. Matsumoto K. Psychological stress-induced enhancement of brain lipid peroxidation via nitric oxide systems and its modulation by anxiolytic and anxiogenic drugs in mice Brain Res 839 1 1999 74 84
37. Moore D.J. Molecular pathophysiology of Parkinson's disease Annu. Rev. Neurosci 28 2005 57 87
38. Murakami Y. Effect of melatonin on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis In Vivo 25 4 2011 641 647
39. Negi G., Kumar A., and Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades J. Pineal Res 50 2 2011 124 131
40. Niranjan R., Nath C., and Shukla R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6 Free Radic. Res 44 11 2010 1304 1316
41. Ortiz G.G. Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders Curr. Neuropharmacol 6 3 2008 203 214
42. Ortiz G.G. Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Metab. Brain Dis 28 4 2013 705 709
43. Ozsoy O. The effect of docosahexaenoic acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B Neurotox. Res 20 3 2011 250 262
44. Pandi-Perumal S.R. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes Neurotox. Res 23 3 2013 267 300
45. Pannu R., and Singh I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms Neurochem. Int 49 2 2006 170 182
46. Papavasiliou P.S. Melatonin and parkinsonism JAMA 221 1 1972 88 89
47. Patki G., and Lau Y.S. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease Pharmacol. Biochem. Behav 99 4 2011 704 711
48. Paxinos G. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight J. Neurosci. Methods 13 2 1985 139 143
49. Pranski E.L. RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-kappaB signaling in dopaminergic cells Neurobiol. Dis 54 2013 264 279
50. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease Parkinsonism Relat. Disord 11 Suppl. 1 2005 S3 S7
51. Pyo J.H. Neuroprotective effect of trans-cinnamaldehyde on the 6-hydroxydopamine-induced dopaminergic injury Biol. Pharm. Bull 36 12 2013 1928 1935
52. Raghavendra V., and Kulkarni S.K. Reversal of morphine tolerance and dependence by melatonin: possible role of central and peripheral benzodiazepine receptors Brain Res 834 1-2 1999 178 181
53. Rauch F., Schwabe K., and Krauss J.K. Effect of deep brain stimulation in the pedunculopontine nucleus on motor function in the rat 6-hydroxydopamine Parkinson model Behav. Brain Res 210 1 2010 46 53
54. Rizelio V. Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease Braz. J. Med. Biol. Res 43 1 2010 85 95
55. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model J. Pineal Res 42 3 2007 247 253
56. Sharma R., McMillan C.R., and Niles L.P. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease J. Pineal Res 43 3 2007 245 254
57. Sharma S.D. Studies on structure activity relationship of some dihydroxy-4-methylcoumarin antioxidants based on their interaction with Fe(III) and ADP Biometals 18 2 2005 143 154
58. Shaw K.M., Stern G.M., and Sandler M. Melatonin and parkinsonism Lancet 1 7797 1973 271
59. Singhal N.K. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol. Neurobiol 45 1 2012 186 199
60. Tanriover G. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease Folia Histochem. Cytobiol 48 3 2010 434 441
61. Thomas B., and Mohanakumar K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum J. Pineal Res 36 1 2004 25 32
62. Tobon-Velasco J.C. 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappaB factors Toxicology 304 2013 109 119
63. Tocharus J., Chongthammakun S., and Govitrapong P. Melatonin inhibits amphetamine-induced nitric oxide synthase mRNA overexpression in microglial cell lines Neurosci. Lett 439 2 2008 134 137
64. Vilar A. Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition Free Radic. Res 48 2 2014 119 128
65. Wang H.M. Inhibition of glycogen synthase kinase-3beta by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes Neurochem. Int 63 5 2013 345 353
66. Willis G.L., and Armstrong S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease Physiol. Behav 66 5 1999 785 795
67. Willis G.L., and Robertson A.D. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in chronic,bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor Pharmacol. Biochem. Behav 79 2004 413 429
68. Xu Y.Q. Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses CNS Neurosci. Ther 19 3 2013 170 177
69. Yoritaka A. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc. Natl. Acad. Sci. U.S.A. 93 7 1996 2696 2701